II

ImageneBio Inc

IMA·NASDAQ

$5.69

+2.3%
HealthcareBiotechnology

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

At a Glance

Live Snapshot
Market Cap$64.18M
EPS-10.7600
P/E Ratio-0.53
Earnings Date07/23/2026

ima

Net Interest Income

Last Annual Value

2.04M

3-Year CAGR

-2%

5-Year CAGR

%

10-Year CAGR

%

II

ImageneBio Inc Competitors Analysis of Net Interest Income

IMA · NASDAQ
CompanyNet Interest Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
IMA logo
ImageneBio Inc
NASDAQ:IMA
2.04M
-34.1%145.1%N/A 
2.93M
-5.6%36.4%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
5.74M
-16.8%N/AN/A
-293.00K
N/AN/AN/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
1.04M
-30.3%73.6%N/A
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
170.26K
N/AN/AN/A
941.00K
20.9%N/AN/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
-1.23M
N/AN/AN/A
-28.96M
N/AN/AN/A
0.00
N/AN/AN/A
-1.44M
N/AN/AN/A
II

ImageneBio Inc Fair Value Envelope

IMA · NASDAQ

Our analysis suggests that IMA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.69, this represents a potential HIDDEN relative to our calculated worth for ImageneBio Inc.

Intrinsic Value
Current Price: $5.69